Mounjaro's GLP mechanism: what makes it different from other weight-loss injections

What does 'GLP' actually stand for, and why does it matter for weight loss?

GLP stands for glucagon-like peptide. GLP-1 is a hormone your gut releases after eating; it signals to the brain that you're full, slows the rate at which food leaves your stomach, and prompts the pancreas to release insulin in response to rising blood sugar. Medicines that mimic this signal (called GLP-1 receptor agonists) have been used in diabetes treatment for over a decade, but their effect on appetite led to their development as weight-management treatments too.

The key thing to understand about GLP-1 receptor agonists is that they are not appetite suppressants in the old-fashioned stimulant sense. They work by amplifying the body's own post-meal hormonal signals rather than overriding the nervous system. That distinction matters clinically: the side-effect profile is driven mainly by the gut (nausea, changes in digestion) rather than the cardiovascular or psychological effects associated with older weight-loss medicines.

The NHS patient information page on tirzepatide explains the mechanism in straightforward terms and is worth reading alongside any consultation. What the 'GLP' label does not tell you, on its own, is which receptors a medicine activates, and that is where Mounjaro stands apart.

How does Mounjaro's dual GIP and GLP-1 action differ from a single-receptor medicine?

GIP (glucose-dependent insulinotropic polypeptide) is a second gut hormone released after eating. For years it was seen as less clinically useful than GLP-1. Tirzepatide changed that view, and our dedicated tirzepatide page explains exactly how the drug's receptor activity reshapes the way researchers now think about GIP. By activating both receptors simultaneously, it produces a combined effect on appetite, gastric emptying, insulin secretion and fat metabolism that a GLP-1-only medicine cannot fully replicate.

The practical upshot showed up clearly in SURMOUNT-5, a head-to-head trial published in the New England Journal of Medicine in 2025, which compared tirzepatide directly against semaglutide 2.4mg (Wegovy) in 751 adults with obesity over 72 weeks. Tirzepatide produced greater average weight reduction. NICE's appraisal of tirzepatide (TA1026) noted that indirect comparisons across the broader evidence base also favour tirzepatide over semaglutide for weight loss.

This does not make tirzepatide automatically the right choice for every person, tolerability, medical history and individual response all matter. But the dual-receptor mechanism is the reason the trial numbers look different, and it is worth understanding rather than taking on faith. Our guide to Mounjaro's GIP and GLP-1 pathways goes deeper into the receptor pharmacology if you want the detail.

Who does Mounjaro's GLP-based licence actually cover?

In the UK, Mounjaro is licensed for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition, and our Mounjaro GLP-1 page sets out exactly how that licence translates into eligibility in practice. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. The licence also covers type 2 diabetes management separately from the weight indication.

A BMI figure alone does not determine whether treatment is appropriate. A prescriber looks at the whole picture: other medicines you take, relevant medical history, contraindications. Treatment starts at 2.5mg, a dose designed to let your system adjust rather than deliver the full therapeutic effect straight away, and is titrated by the prescriber over time.

If you want a quick sense of where you might stand before speaking to anyone, the NHS BMI calculator takes under a minute and gives you a number to bring to your consultation. It is not a clinical decision, but it is a useful starting point. For a broader look at what the NICE recommendation covers, our Mounjaro overview sets out the eligibility detail alongside the evidence.

For people who do not qualify for NHS treatment or would prefer not to wait, accessing Mounjaro through a regulated private pharmacy follows the same clinical standards, a prescriber still reviews your case before any medicine is issued. The cost context for private treatment is covered separately on our weight-loss treatments page, where current pricing is shown transparently alongside what is included.

What does the GLP mechanism mean for side effects day to day?

Because tirzepatide works through gut-hormone pathways, the most common side effects are gastrointestinal: nausea, changes in bowel habit, indigestion, burping and occasionally vomiting. These tend to be most noticeable in the first few weeks of treatment or after a dose increase, and they often ease as the body adapts. They are not a sign that something is going wrong; they are largely a result of slowed gastric emptying doing its job.

A small number of people experience more significant effects. Acute pancreatitis is a known but infrequent risk with GLP-1 medicines, the MHRA issued a Drug Safety Update in January 2026 specifically highlighting it. The warning sign is severe stomach pain that radiates to the back, with or without vomiting; that warrants urgent medical attention, not a wait-and-see approach.

The GLP-1 and tirzepatide side-effect guide covers the full profile in more detail, including which symptoms ease on their own and which need a call to your prescriber or, in some cases, 999. Any suspected side effect can also be reported to the MHRA via the Yellow Card scheme, patients can submit reports directly, not just healthcare professionals.

If you think you might be suitable and would like a clinician to review your history, check your eligibility with our prescribers, the consultation is free, and a GPhC-registered prescriber, not an algorithm, reads every response.